The team, led by Akash Kumar and Deepak Sehgal of the Shiv Nadar Institution of Eminence, with collaborators at the All India Institute of Medical Sciences, the University of Pittsburgh School of Medicine and King Saud University, began with computational work rather than wet-lab experiments. Using AlphaFold to predict the three-dimensional structure of the membrane protein from the Delta variant, refined through the YASARA energy-minimization server, they docked two copies of the protein together with ClusPro and analyzed the resulting dimer interface with PDBSum. The interaction analysis revealed one salt bridge, seven hydrogen bonds and 215 non-bonded van der Waals contacts holding the homodimer together. Four residues emerged as particularly important: glutamate 115, tyrosine 39, lysine 50 and glutamate 135. Glutamate 115 sits in the hinge region that governs the switch between the long and short conformations of the membrane protein dimer, a transition that cryo-electron microscopy studies had previously shown to be essential for virus assembly. Glutamate 135 lies in the C-terminal tail, where acidic residues help stabilize the intermolecular contacts needed for higher-order particle structure.

Molecular dynamics simulations then put the docked dimer through its paces. The team ran a 500-nanosecond simulation at 300 Kelvin and 1 bar using the OPLS force field in Desmond, tracking root-mean-square deviation, residue fluctuations, radius of gyration and solvent-accessible surface area. The results painted a picture of a rigid core with flexible edges: the C-alpha RMSD rose sharply at first, then plateaued at a stable value of roughly 8 to 9 angstroms, indicating that the complex relaxed into a new but durable conformation. The radius of gyration decreased and stabilized, and the solvent-accessible surface area declined, both signs that the dimer was packing more tightly over time. Only the peripheral helices and terminal tails showed meaningful mobility, consistent with the idea that membrane protein dimers act as stiff scaffolds that impose curvature on the viral membrane and provide a platform onto which the spike, envelope and nucleocapsid proteins are organized.

With the computational groundwork laid, the researchers turned to the baculovirus expression vector system, a workhorse of industrial protein production. They cloned the membrane gene into a recombinant bacmid and transfected Sf-21 insect cells, generating a P0 viral stock that was amplified and used to infect 500 million cells at a multiplicity of infection of 10. After 96 hours of incubation at 27 degrees Celsius, the cells were lysed with a Dounce homogenizer and sonication, and both the lysate and the concentrated culture medium were loaded onto a 20 to 80 percent sucrose gradient for ultracentrifugation at 27,000 rpm in an SW41 Ti rotor. A visible ring appeared at the junction of the 40 and 50 percent sucrose layers, corresponding to a particle density of 1.16 to 1.18 grams per milliliter, closely matching the density reported for purified SARS-CoV-2 virus-like particles and infectious coronavirions in earlier studies. SDS-PAGE and Western blotting confirmed the presence of the roughly 25-kilodalton membrane protein in these fractions, while uninfected Sf-21 cell controls produced no comparable structures.

The biophysical characterization confirmed that these were genuine, discrete particles rather than protein aggregates. Dynamic light scattering on a Horiba Zeta Sizer measured a hydrodynamic diameter of approximately 225 nanometers and a zeta potential of around minus 15 to minus 25 millivolts, the negative surface charge typical of enveloped virus particles. Field-emission scanning electron microscopy, at 40,000-fold magnification, revealed spherical to slightly pleomorphic particles of roughly 180 to 200 nanometers, and transmission electron microscopy of negatively stained samples showed numerous electron-dense spherical particles of about 200 nanometers embedded in a background of amorphous material. Taken together, the DLS, FESEM, TEM and immunoblotting data support the conclusion that expression of the membrane protein alone is sufficient to drive the budding of virus-like particles in this system, a capability that had not previously been demonstrated for the SARS-CoV-2 membrane protein in isolation.

The immunological evaluation was carried out in female BALB/c mice, aged four to six weeks, under protocols approved by the Institutional Animal Ethics Committee of Rodent Research India and compliant with Indian CCSEA standards. Each mouse received 100 micrograms of purified particles subcutaneously with 0.5 percent aluminum hydroxide adjuvant, while control animals received sterile phosphate-buffered saline. Blood samples collected at days 7, 14, 35 and 45 told a clear story. Serum IgG in the immunized group was already elevated by day 7, remained above control levels at all subsequent time points, and showed a gradual decline at days 35 and 45, a pattern consistent with a strong primary immune response rather than a loss of immunological memory. IgM peaked around day 7 and then declined but stayed above control levels through day 45. IgA, typically associated with mucosal immunity, was higher in the immunized group at every time point, indicating that the particles could stimulate class-switched antibody responses in addition to the early IgM wave. Isotype profiling on the final serum collection showed a broad antibody repertoire, with measurable IgG subclasses, strong IgM reactivity, and robust signals for kappa light chains and total heavy-plus-light chains, confirming active production of functional immunoglobulins.

The cellular arm of immunity proved equally responsive. Sandwich ELISA measured serum interferon-gamma, which was consistently higher in the immunized group with peak levels around day 14 and sustained elevation at days 35 and 45, a signature of T helper type 1 activation that mirrors findings from earlier SARS-CoV and SARS-CoV-2 structural protein vaccine studies. Quantitative real-time PCR on splenocytes deepened this picture. Using the 2^-ΔΔCt method on TRIzol-extracted RNA converted to cDNA, the team found markedly elevated expression of interferon-gamma, interleukin-2 and interleukin-12, together indicating a dominant Th1 pattern of the kind observed in SARS-CoV-2-specific T cells during infection and vaccination. Importantly, the particles also raised interleukin-4 and interleukin-13, showing that Th2 responses supporting antibody class switching were engaged as well, and a modest rise in interleukin-10 suggested a regulatory brake that could prevent excessive inflammation while preserving protective immunity. Th17 and transforming growth factor beta components rounded out a balanced cytokine profile. Statistical significance was assessed with two-way ANOVA and Tukey’s post-hoc test for the ELISA data and Mann-Whitney tests for the qRT-PCR data.

The question of neutralization, however, received a sober answer. Because the membrane protein has only a short N-terminal ectodomain and sits mostly embedded in the viral envelope, antibodies directed against it are not expected to block viral attachment or entry, and indeed the M-protein particles alone did not induce detectable neutralizing activity. This distinguishes them sharply from spike-targeted vaccines, which elicit the receptor-blocking antibodies that prevent infection. Yet the team argues that this is not a disqualifying limitation. The membrane protein has remained highly conserved across the many SARS-CoV-2 variants that have emerged since the pandemic began, including the Delta variant that originated in India, whereas spike has mutated relentlessly under immune pressure. A vaccine component built on the membrane protein could therefore provide durable immune memory and T-cell help that remains effective regardless of how the spike evolves, potentially serving as a conserved backbone in combination with variant-matched spike antigens. The researchers’ previous work on Membrane-Envelope particles had already shown antigenicity and neutralization activity, and co-expression of M and E proteins is known to enhance virion assembly and produce particles more faithful to the native virus, suggesting that head-to-head comparisons of M-only versus M-plus-E particles in larger animal cohorts are a natural next step.

The study also charts a path for refining the platform itself. Targeted mutations at glutamate 115 or glutamate 135 could probe how changes at the dimer interface affect particle formation, stability and immunogenicity, while tuning the lipid composition of the production system to favor lipids such as ceramide-1-phosphate, which is known to stabilize assembly-competent conformations of the membrane protein, might yield higher-quality particles. More definitive structural work, including immunogold labeling, cryo-electron microscopy and cryo-electron tomography, will be needed to visualize exactly how the membrane protein is oriented within the assembled particles. And before any translational claims can be made, neutralization assays, virus challenge studies and protection-efficacy experiments will be essential. For now, the finding stands as a striking demonstration of molecular self-assembly: one small, 25-kilodalton protein, acting alone in insect cells, can build a virus-like shell that the mouse immune system recognizes and attacks with vigor, opening a new avenue in the search for coronavirus vaccines built not on the shifting spike, but on the stable scaffold beneath it.

Central to this research is an internal protein of SARS-CoV-2, commonly referred to as the nucleocapsid protein, which encapsulates the virus’s genetic material. Unlike the spike protein that frequently mutates under selective pressure from neutralizing antibodies, the nucleocapsid protein remains relatively conserved because of its critical role in viral structure and replication. This intrinsic stability makes it a compelling candidate for vaccine design. The research team found that peptides derived from this protein are presented on the surface of infected human cells by an immune presentation molecule known as HLA-C.

HLA-C is a variant of the major histocompatibility complex (MHC) class I molecules, which are integral to the immune system’s ability to detect viral infections. These molecules display intracellular peptides on the cell surface, essentially signaling the presence of infection to cytotoxic CD8+ T cells, or killer T cells. Upon recognition of viral peptides bound to HLA-C, these T cells initiate an immune response to destroy the infected cells, thereby curbing viral propagation. The discovery highlights that killer T cells recognize the nucleocapsid peptide in conjunction with HLA-C, mounting a potent antiviral response.

Professor Stephanie Gras, who leads the La Trobe research team, emphasizes that this mode of immune recognition could overcome a significant limitation of current vaccine strategies. Vaccines targeting the spike protein are highly effective initially, yet their protection wanes as new variants emerge carrying spike mutations that allow immune escape. By contrast, an immunity elicited against the conserved internal nucleocapsid peptide could maintain protection across multiple SARS-CoV-2 variants, including those yet to evolve, providing a crucial advantage in pandemic control.

The molecular basis of this T cell response was elucidated through sophisticated experimental methods, involving structural biology and immunological assays. The team employed high-resolution techniques to analyze how the nucleocapsid-derived peptide binds within the groove of HLA-C molecules and how this complex is recognized by CD8+ T cell receptors. This deep mechanistic insight provides a blueprint for the rational design of vaccines that harness HLA-C-restricted T cell immunity, potentially enabling the induction of robust cellular immunity alongside existing antibody responses.

Further implications of this research lie in the prospect of reducing the frequency of booster vaccinations needed to sustain immunity. Current vaccines require repeated booster doses to combat waning antibody levels and emerging variants, a strategy that is challenging logistically and may face public acceptance hurdles. Vaccines that stimulate killer T cells targeting stable viral epitopes could confer durable immunity, lowering the need for frequent boosters and enhancing long-term population-level protection against COVID-19.

Another critical benefit of targeting the nucleocapsid protein could be its impact on Long COVID, a debilitating post-viral syndrome affecting approximately 10% of the infected population. Persistent viral reservoirs and immune dysregulation are hypothesized contributors to Long COVID, and enhancing T cell-mediated clearance of infected cells might mitigate these complications. Professor Gras notes that preventing repeated infections and promoting efficient viral clearance could reduce the incidence and severity of Long COVID, underscoring the societal importance of improved vaccine designs.

The collaborative nature of this research is noteworthy, involving advanced data collection from the Australian Synchrotron and interdisciplinary expertise from immunology, structural biology, and virology. The integration of these disciplines allowed the team to comprehensively characterize the immune response and to validate the potential of nucleocapsid peptides as critical immune targets. This synergy exemplifies how cutting-edge infrastructure and international cooperation can accelerate vital scientific breakthroughs.

Funding for this landmark study was provided by major Australian health bodies, including the National Health and Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF). The support underscores the importance placed on innovative COVID-19 research in protecting global health and guiding public health policy. The financial backing has also enabled the team to expand their scope toward investigating other post-viral syndromes related to SARS-CoV-2 infection.

Professor Gras is poised to lead a new research center at La Trobe University dedicated to unraveling the causes and mechanisms behind Long COVID and other severe post-viral conditions, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis (MS). The Post-Acute Viral Infection diseases Group (PAVING) Centre of Research Excellence will leverage an initial $3 million funding investment to advance understanding and develop targeted therapies for these complex diseases that significantly impair quality of life.

This pioneering identification of a potent antiviral T cell response guided by HLA-C presents a dynamic framework for next-generation vaccine development not only for COVID-19 but potentially other viral infections where internal protein epitopes remain more conserved than surface antigens. The strategic redirection toward conserved internal viral targets represents an evolutionary leap in vaccine science, offering hope for lasting protection against rapidly mutating pathogens. With ongoing studies and clinical validations, this research may pave the way for safer, more effective vaccines that keep pace with viral evolution.

As the global community continues to grapple with the challenges posed by SARS-CoV-2 and its variants, this transformative research offers a beacon of hope, grounding future vaccine strategies in the immune system’s capacity to recognize immutable viral elements. This approach, blending cellular immunology with precise molecular insights, could redefine how humanity prepares for and ultimately controls viral pandemics in the decades to come.

Subject of Research: Cells

Article Title: Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope

News Publication Date: 28-Aug-2025

Web References: DOI: 10.1038/s41467-025-63288-3

References: Research published in Nature Communications

Keywords: COVID 19, Vaccination, Coronavirus

The upcoming trial, slated to commence in the spring of this year, has renewed hopes for innovative intervention against COVID-19, especially in light of the ongoing presence of the virus despite a decline in cases since the height of the pandemic. The nasal vaccine technology boasts the potential to not only induce immunity in the upper respiratory system, where the virus initially enters the body, but may also play a crucial role in halting transmission. Conventional COVID-19 vaccines primarily administered via injection into the arm or leg have proved effective in reducing serious illness and fatalities but have not been shown to completely prevent the spread of the virus.

The clinical trial will assess the vaccine’s safety and efficacy and will involve 80 adult participants aged 18 to 64. These individuals will be randomly placed into one of four groups, receiving either a low-dose or high-dose version of the vaccine through intranasal or inhaled routes. The primary objective dictates a focus on safety; however, the study will also monitor immune responses via antibody production and will track any breakthrough COVID-19 cases that occur. This multifaceted evaluation is essential for understanding the vaccine’s capacity to invoke robust immune defenses.

Expressions of excitement regarding this progression into human trials are palpable among the research team and university officials. Doug E. Frantz, PhD, the Vice Chancellor for Innovation and Commercialization at WashU, has vocalized his enthusiasm for the technology’s potential. He emphasizes that this nasal vaccination technology could significantly alleviate the global burden of respiratory infections and germs, underscoring its adaptability for variants of COVID-19, influenza strains, and other respiratory pathogens that have been the scourge of communities worldwide.

Currently, a version of the nasal vaccine has been available in India since 2022, thanks to a licensing agreement struck between Washington University and Bharat Biotech, an Indian biotechnology firm. This prior implementation provides a preliminary insight into the vaccine’s performance in humans, underscoring the importance of its transition into U.S. trials and offering anticipation for its potential global impact.

The research has received funding from Project NextGen, a federal initiative aimed at the development of advanced COVID-19 vaccines and therapeutics through collaborations between public and private sectors. This emphasis on partnership signifies a forward-looking approach to vaccine development that aligns with evolving global public health needs. The vaccine’s formulation incorporates findings and innovations stemming from past studies that have demonstrated promising outcomes.

The nasal vaccine, originally co-developed by a distinguished research team at WashU Medicine, is a product of innovation and scientific inquiry. Researchers Michael S. Diamond, MD, PhD, and David T. Curiel, MD, PhD, played critical roles in engineering the vaccine by inserting genetic material from SARS-CoV-2 into a non-pathogenic adenovirus. This adenovirus serves as a vector to deliver the SARS-CoV-2 protein directly into the nasal cavity, allowing the immune system to respond effectively without causing illness.

In preclinical studies, particularly in animal models, the nasal vaccine exhibited its ability to stimulate robust immune responses, especially in the respiratory tract, which is paramount for countering respiratory infections. Experiments conducted in recent years illustrated that the vaccine could entirely prevent infection in the nasal passages and lungs of vaccinated animals, suggesting its use could dramatically curtail viral replication and subsequent infection in human populations.

The potential to reduce not just the severity of COVID-19 illness but also its transmission makes this vaccine particularly noteworthy. There is a growing consensus among researchers that the ability to prevent the virus from spreading within communities could profoundly alter the management of respiratory illnesses in the future. This aligns with broader public health goals and the ongoing efforts to minimize the overall burden of infectious diseases.

As the trial approaches, expectations and hopes are high for the findings that will emerge from this initial phase. Should the vaccine demonstrate safety and immunogenicity, it could pave the way for subsequent phases that would explore larger populations, broader demographics, and, ultimately, its deployment in general populations. The promise of an effective nasal vaccine introduces a new chapter in the ongoing battle against COVID-19 and enhances our defense against future respiratory viruses that could emerge.

The necessity for continually updated vaccination strategies is underscored by the evolving landscape of viral infections. This nasal vaccine holds the promise of adaptability, potentially targeting not only variants of SARS-CoV-2 but also being repurposed for influenza and other seasonal viruses. Its successful development could reshape our understanding of vaccine delivery and its implications for future pandemic preparedness, offering a glimmer of hope amidst continued global health challenges.

In conclusion, the march toward human trials for a nasal COVID-19 vaccine is a milestone in vaccine research and development. Strong initial results, combined with a dedicated team and strategic partnerships, could soon yield a revolutionary approach to disease prevention that emphasizes both individual health and community safety. With the support of various funding avenues and expertise from WashU Medicine, the world watches with bated breath for the outcomes of this promising research endeavor, as it may very well set a new standard in vaccine delivery mechanisms aimed at respiratory pathogens.

Subject of Research: Vaccine Development
Article Title: Nasal Vaccine for COVID-19 Enters Clinical Trials
News Publication Date: October 2023
Web References: www.wustl.edu
References: Washington University Press Releases
Image Credits: Washington University in St. Louis

Keywords

COVID-19, nasal vaccination, immune response, vaccine development, respiratory viruses, public health.